The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

<table>Comparison of changes in allograft function between the responder and nonresponder groups. eGFR showed sustained decline during 6 months before RIT in both responder and nonresponder groups. After RIT, eGFR in the responder group showed significant increase; however, decline of eGFR was persisted in the nonresponder group.</table>

Journal of Immunology Research

fig1

Figure 1

Figure 1: The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients 

Figure 1 | The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients 